AI assistant
Minerva Neurosciences, Inc. — Director's Dealing 2016
Dec 16, 2016
35086_dirs_2016-12-16_ffa08f95-987d-427c-bbdf-6034aee39182.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Minerva Neurosciences, Inc. (NERV)
CIK: 0001598646
Period of Report: 2016-12-14
Reporting Person: Luthringer Remy (Director, President & CEO)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2016-12-14 | Restricted Stock Unit | $ | A | 75000 | Acquired | Common Stock (75000) | Direct | |
| 2016-12-14 | Stock Option (Right to Buy) | $13.45 | A | 150000 | Acquired | 2026-12-13 | Common Stock (150000) | Direct |
Footnotes
F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock
F2: Represents shares issuable upon the vesting of restricted stock units ("RSUs") awarded to the Reporting Person on December 14, 2016. The
RSUs vest in 4 equal annual installments beginning on December 14, 2017 and will be fully vested on December 14, 2020, in all cases so long
as there has been no break in the Reporting Person's continuous service through such date.
F3: The exercise price is the closing price of the Issuer's common stock on December 14, 2016.
F4: This option shall vest as follows: 25% on December 14, 2017 and then in quarterly installments over 3 years thereafter.